Our partnership with Amgen led to the first international clinical trial ever performed in IgG4-RD. The trial, named MITIGATE, was a landmark moment for IgG4ward!, Amgen, and patients living with this rare disease. The MITIGATE trial enrolled patients from 22 different countries to participate in a B cell depletion medicine called inebilizumab. The completion of this stage 3 clinical trial revealed that inebilizumab reduced the risk of IgG4-RD flare by 87% compared to the standard treatment arm. While much work remains ahead, IgG4-RD patients now have access to an effective FDA-approved drug.